导语：新型口服磷酸二酯酶4B（PDE4B）抑制剂nerandomilast在进展性肺纤维化（PPF）患者中开展的关键Ⅲ期临床试验FIBRONEER-ILD达到主要研究终点，于今日重磅发表于国际顶尖医学期刊《新英格兰医学杂志》（NEJM）。结果显示，第 ...

City of Hope will present novel cancer treatment approaches, targeted therapies, and supportive care interventions at the ...

近日，精智未来（ChromX Health）与华中科技大学同济医学院附属同济医院张惠兰教授团队在国际权威期刊上发表了文章《Exploring exhaled volatile organic compounds as potential ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

Electronic nose technology was able to distinguish between multiple interstitial lung disease types with good accuracy.

Researchers are working to redefine diagnosis and treatment with data-driven tools aimed at identifying patients earlier and ...

Mold thrives where moisture lingers. Spores can flourish after floods, heavy rains, or the unseen drip of a leaky pipe, ...

Among adults with interstitial lung disease requiring ICU care, women faced a lower adjusted likelihood for mortality vs. men ...

The following is a summary of “Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological ...

In a pioneering effort to transform the diagnosis and treatment of Interstitial Lung Diseases (ILD), ''BuILD Summit 2025,'' the first-ever ILD-focused medical summit in South India, will be held here ...